Targeted molecular therapy for myasthenia gravis
- PMID: 34146498
- DOI: 10.1016/S1474-4422(21)00173-3
Targeted molecular therapy for myasthenia gravis
Conflict of interest statement
I report receiving speakers’ fees from Alexion Pharmaceuticals, the Japan Blood Products Organization, and Asahi Kasei Medical; and I have participated on advisory board meetings of Alexion Pharmaceuticals.
Comment on
-
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
